Cortechs.ai | Volumetric quantification of focal atrophy in AD

Volumetric quantification of focal atrophy in AD

Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer’s disease

Volumetric analysis of structural MR images of the brain may provide quantitative evidence of neurodegeneration and help identify patients at risk for rapid clinical deterioration. This note describes tests of a fully automated MR imaging postprocessing system for volumetric analysis of structures (such as the hippocampus) known to be affected in early Alzheimer disease (AD). The system yielded results that correlated highly with independent computer-aided manual segmentation and were sensitive to the anatomic atrophy characteristic of mild AD.

NeuroQuant® Results Published in the American Journal of Neuroradiology.

[button]Download[/button]

More Resources

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”

07/16/2025

Advancing Prostate MRI with Restriction Spectrum Imaging

Why is OnQ Prostate unique, and what makes it a game-changer for clinicians?

07/08/2025

Enhancing Neuroimaging Insights: LVV & ICV Quantification and Midline Shift Indexing with NeuroAlign CT

Time-sensitive and precise diagnostic imaging can mean the difference between rapid intervention and devastating outcomes.

07/07/2025

When to repeat an MRI scan for NeuroQuant®

NeuroQuant® can process an array of exams. However, there are some circumstances that will require you to repeat a scan.

06/27/2025

Understanding Microvascular Ischemic Disease and the Value of NeuroQuant Microvascular Reports

Accurate, objective data is important in the effort to standardize reporting on vascular lesions and their associated pathologies.

06/16/2025

Seeing Alzheimer’s More Clearly: How PET Imaging Is Changing the Game

PET imaging is transforming how we detect and monitor Alzheimer’s disease, enabling earlier diagnosis, better disease tracking, and more personalized treatment.
Scroll to Top